Open Accessibility Menu

Coronavirus (COVID-19) Vaccine Update Click here to learn more.

For information about COVID-19 or to view additional resources, please click here.

Virtual Health Visits - Frequently Asked Questions

How do virtual health visits work?

We use the secure video platform, Zoom, a health information (HIPAA) compliant video conferencing system that allows you to have a video conference-based visit with your GW Urology physician or provider. You will need to have a computer, tablet or smart phone with a front facing camera to participate in the virtual health visit.

The Zoom application is available for download to use on smart phones and tablets. The apps are available in the Apple App Store and on Google Play. See instructions below for steps to set up your computer, tablet or phone for Zoom. Zoom is a free video communications software and there is no charge for using Zoom.

What are the next steps after downloading the software?

  • Once you have downloaded the software, a box will prompt you to enter your name. Please enter your first and last name.
  • The next prompt will ask you how you’d like the audio (sound source) for the meeting to be connected. It is best to connect by computer or the audio on your tablet or smart phone
  • Be sure that your microphone is not muted and that your speakers are not muted. This way you and your provider can speak to each other. You will also need to make sure that your video stream is “started” so that you can see each other. You may have to hover your mouse over the screen on your computer or tap the screen on your phone to get this toolbar to appear.
  • You should be able to see and talk to your provider. At the beginning of your appointment, your provider will also ask you for an alternate contact number at which to reach you, just in case you have trouble getting started or if you get disconnected during the appointment.

This set up does not have to be done again for subsequent visits.

Is this service covered by insurance?

Online care is covered by Medicare and most insurance plans.

Is my personal health information kept confidential?

Yes! Our online dermatology care platform is secure and 100% HIPAA and HITECH compliant.

What urologic conditions can be treated with a virtual appointment?

Type of appointments that can be booked through virtual health care include:

General Urology

  • Benign Prostatic Enlargement (BPH)
  • Bothersome urinary symptoms
  • Diagnostic and Laboratory Results Follow-up
  • Urinary Tract Infections
  • Blood in the Urine (Hematuria)
  • Second Opinions & Consults

Urologic Cancers

  • Prostate Cancer Treatment
  • Prostate Cancer
  • PSA Screening
  • Kidney Mass & Kidney Cancer
  • Bladder Mass & Bladder Cancer
  • Testis Cancer

Kidney Stones

  • Metabolic management
  • Surgical treatments

Reconstructive Urology

  • Urethral stricture
  • Repair of traumatic injury
  • Transition from Pediatric to Adult Urology
  • Female and Male Incontinence
  • LGBTQ Specialized Services: Compassionate Care, Gender Affirmation Surgery

Female Urology/ Urogynecology

  • Pelvic Organ Prolapse (Bladder/Uterus)
  • Women’s Sexual Health
  • Pelvic Floor Disorders
  • Urinary incontinence
  • Postpartum Pelvic Floor Evaluation

Male Sexual Health

  • Male Fertility Evaluations and Care
  • Vasectomy Reversal
  • Low Testosterone
  • Male Pelvic Pain
  • Erectile Dysfunction

Clinical Trials

  • Primary objective:
    To compare overall survival in metastatic prostate cancer patients who are randomized to standard systemic therapy (SST) plus definitive treatment of the primary tumor versus standard systemic therapy alone.

    Secondary objectives:

    1. To compare overall survival in metastatic prostate cancer patients who received SST plus surgical excision of the primary tumor versus SST alone in the subset who specify the surgical intent stratification factor.
    2. To compare the rate of symptomatic local progression between the treatment arms.
    3. To compare progression-free survival (PFS) between the two treatment arms.
    4. To compare rates of progression-free survival between arms for the subsets of patients with and without metastasis directed therapy (MDT) to oligometastatic sites.

    Inclusion Criteria:

    1. All patients must have a histologically or cytologically proven diagnosis of adenocarcinoma of the prostate. Patients with pure small cell carcinoma* (SCC), sarcomatoid, or squamous cell carcinoma are not eligible. (*morphology must be consistent with SCC; synaptophysin or chromogranin positive by immunohistochemical staining is insufficient to diagnose SCC).
    2. Patients must have an intact prostate. No prior local therapy for prostate adenocarcinoma is allowed (e.g., brachytherapy, high-intensity focused ultrasound [HIFU], cryotherapy, laser ablative therapies). Any prior therapy for benign conditions, such as obstruction, are acceptable (e.g., transurethral resection of the prostate, greenlight laser ablation, microwave ablation).
    3. Patients must have evidence of metastatic disease on technetium bone scan and computed tomography (CT) or magnetic resonance imaging (MRI) within 42 days prior to starting standard systemic therapy. Metastatic disease that is detected by positron emission tomography (PET) scan only (sodium fluoride [NaF], prostate-specific membrane antigen [PSMA], anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid [FACBC], carbon [C]11) but not conventional imaging (technetium [Tc]99 bone scan, CT or MRI) or solitary metastases by conventional imaging, must be confirmed histologically or cytologically.
    4. Patients with known brain metastases are not eligible. Brain imaging studies are not required for eligibility if the patient has no neurologic signs or symptoms suggestive of brain metastasis. If brain imaging studies are performed, they must be negative for disease.
    5. Patients must have received no more than 28 weeks of standard systemic therapy (SST). SST is defined as current National Comprehensive Cancer Network (NCCN) guidelines for metastatic prostate cancer.
    6. Patients must not have progressed while on SST.
    7. Patients with oligometastatic prostate cancer may receive metastasis directed therapy to up to four sites of disease prior to randomization.
    8. Patients must have a complete physical examination and medical history within 28 days prior to registration.
    9. Patients must have a PSA documented prior to initiation of SST and within 28 days prior to registration. Any additional PSAs measured while receiving SST should be recorded.
    10. Patients must have a testosterone lab documented within 28 days prior to randomization. Any additional testosterone labs measured while receiving SST should be recorded as well as pretreatment initiation if available.
    11. No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, adequately treated stage 0, I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years.
    12. Patients must be offered the opportunity to participate in translational medicine studies and specimen banking for future studies.
    13. Patients who can complete Patient-Reported Outcome instruments in English, Spanish or French, must participate in the quality of life studies.
    14. Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.